Iofina extracts iodine from oilfield brine in the United States, one of the few Western producers in a market roughly 90% controlled by Chile and Japan. Record production, rising cash and a big new Permian plant give it genuine momentum — though its fortunes remain tied to a single, volatile Commodity price.
Introduction
Iodine is a small market with an outsized concentration problem: about 90% of global Supply comes from just Chile and Japan. Iofina occupies the rare position of a Western producer, pulling iodine from oilfield brine in the American heartland. With record output, a strengthening Balance Sheet and its largest-ever plant about to start up, the company has real momentum — provided the iodine price, on which everything hinges, stays firm.
Company overview
Iofina is an AIM-listed company that produces iodine from oil- and gas-associated brine in the United States, primarily Oklahoma and now the Permian Basin , using its patented IOsorb extraction technology. Its IofinaChem arm converts crystalline iodine into higher-value specialty Derivatives for animal health, pharma and biocides. In early August 2026 the shares traded around 53p for a Market Capitalisation of roughly £102m. A 2025 capital reduction created distributable reserves, opening the door to future dividends or Buybacks , though none has yet been declared.
Latest developments
Growth has accelerated. In December 2025 Iofina agreed a deal with Western Midstream to build its largest-ever plant in the Permian Basin, drawing on a large brine supply and targeting a substantial step-up in crystalline-iodine output, with startup expected in the third quarter of 2026. Full-year 2025 results, reported in April 2026, described another record year, and by mid-2026 the company had beaten its own upgraded production guidance, with first-half output up 29% year on year. It also expanded brine supply for an Oklahoma plant and grew its animal-feed derivative into one of IofinaChem’s highest-volume products.
The Permian plant is the centrepiece of a longer-term ambition: management has set a medium-term target of 2,000 tonnes a year of iodine, well above current levels, and is in talks on further plant partnerships. The Western Midstream structure, in which the brine partner provides feedstock on a Royalty basis, keeps Iofina’s own capital cost per plant modest — a capital-light way to scale that has helped drive rising cash generation.
Financial performance
The 2025 accounts were strong. Revenue rose 22% to about US$66.5m, adjusted EBITDA jumped 56% to US$11.8m, and Net Income more than doubled to US$7.9m, with iodine production up 17% to 743 tonnes and the average realised iodine price up 8% to around US$74 a kilogram. The company ended the year in a net cash position of about US$5m, and the capital reduction created capacity for Shareholder returns. First-half 2026 production of 393 tonnes, up 29%, and firm iodine pricing point to another year of growth, funded largely from internal Cash Flow .
Industry outlook
The iodine market is tight and concentrated. Global consumption is approaching 40,000 tonnes a year, with roughly 90% of supply from Chile and Japan, and the board expects prices to remain firm above US$70 a kilogram on supportive supply-demand fundamentals. The largest Demand driver is iodinated X-ray and CT contrast media, with secondary demand from LCD screens, pharmaceuticals, biocides and animal health, and emerging long-term uses in solar cells and refrigerants. The main supply risk is new Chilean capacity coming on stream, which could pressure prices from 2026 onward.
Bull case
The bull case is Scarcity plus momentum. Iofina is one of few Western iodine producers in a market dominated by two countries, offering a security-of-supply premium. Its capital-light growth model — with brine partners funding feedstock access — has delivered record production and rising cash, while Diversification into higher-margin derivatives reduces pure commodity exposure. The new Permian plant and a 2,000-tonne target give a visible growth path, and a strengthened balance sheet could support future returns.
Bear case and risks
The bear case is single-commodity dependence and resource risk. Revenue is heavily geared to the iodine price, and new Chilean supply could pressure it. The Business relies entirely on US oilfield brine — an unusual, third-party-operated and potentially depleting resource exposed to well decline and disposal regulation — and carries some customer concentration. No Dividend has yet been paid despite the reserve creation, and as a small-cap the shares are relatively Illiquid .
Key catalysts
Catalysts include first production from the new Permian plant, expected late in the third quarter of 2026, the Oklahoma brine pipeline expansion, delivery against second-half production guidance, further IOsorb partnerships toward the 2,000-tonne target, the iodine price trajectory against incoming Chilean supply, and any move to begin dividends or buybacks.
Conclusion
Iofina has quietly built something distinctive: a growing, cash-generative Western iodine producer in a market almost no one else in the West serves. Record output, a big new plant and a capital-light growth model give it genuine momentum, and firm iodine prices are flowing through to profit. The catch is inescapable — this is a bet on one volatile commodity, sourced from a finite, third-party brine resource. Manage those risks, and the scarcity story makes Iofina hard to ignore.
The next twelve to eighteen months should be unusually informative. Startup of the Permian plant will test whether the capital-light Partnership model can be replicated at scale, and the arrival of new Chilean supply will test how much of the recent price strength is structural rather than cyclical. If Iofina can grow volumes into a still-firm price and begin returning cash, the Investment case broadens from a commodity trade into something closer to a quality small-cap industrial.






Please wait processing your request...